Show simple item record

dc.contributor.authorFord, N
dc.date.accessioned2008-02-13T01:24:49Z
dc.date.available2008-02-13T01:24:49Z
dc.date.issued2003-06-14
dc.identifier.citationPublic health and Company Wealth. 2003, 326 (7402):1296 BMJen
dc.identifier.issn1468-5833
dc.identifier.pmid12805159
dc.identifier.doi10.1136/bmj.326.7402.1296
dc.identifier.urihttp://hdl.handle.net/10144/18135
dc.descriptionTo obtain this article, click on "Additional Links"
dc.language.isoenen
dc.publisherPublished by: BMJ Publishing Group Ltd
dc.relation.urlhttp://www.bmj.com/cgi/content/full/326/7402/1296
dc.rightsArchived on this site with kind permission from BMJ.en
dc.subject.meshAnti-HIV Agentsen
dc.subject.meshDeveloping Countriesen
dc.subject.meshDrug Costsen
dc.subject.meshDrug Industryen
dc.subject.meshHealth Services Accessibilityen
dc.subject.meshHumansen
dc.titlePublic Health and Company Wealth.en
dc.contributor.departmentMédecins Sans Frontières, London EC1N 8QX. nathan.ford@london.msf.orgen
dc.identifier.journalBMJ/British Medical Journalen


This item appears in the following Collection(s)

Show simple item record